Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: A survey study

Journal of the American Osteopathic Association

Volumn 112, Issue 1, 2012, Pages 22-28

  Stoll, Sharon S ^a,b   Nieves, Christine ^a   Tabby, David Stuart ^a   Schwartzman, Robert ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN; VITAMIN D;

ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; ARTICLE; FEMALE; HEALTH CARE SURVEY; HUMAN; MALE; MASSAGE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE SCLEROSIS; OSTEOPATHIC MEDICINE; PHYSIOTHERAPY; STATISTICS;

ACUPUNCTURE THERAPY; ADULT; COMBINED MODALITY THERAPY; COMPLEMENTARY THERAPIES; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MANIPULATION, OSTEOPATHIC; MASSAGE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHYSICAL THERAPY MODALITIES; VITAMIN D; VITAMINS;

EID: 84856777225     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Manag Care Pharm. 2009; 15(7):543-555.
2. Apel A, Greim B, König N, Zettl UK. Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis [published online ahead of print June 19, 2006]. Neuro. 2006;253(10):1331-1336.
3. Marrie RA, Hadjimichael O, Vollmer T. Predictors of alternative medicine use by multiple sclerosis patients. Mult Scler. 2003;9(5):461-466.
4. Schwartz CE, Laitin E, Brotman S, LaRocca N. Utilization of unconventional treatments by persons with MS: is it alternative or complementary? Neurolog. 1999;52(3):626-629.
5. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis. meta-analysis [published online ahead of print March 19, 2004]. BMJ. 2004;328(7442):731-735.
6. Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neuro. 2008;64(2):143-148.
7. Brown RF, Tennant CC, Sharrock M, Hodgkinson S, Dunn SM, Pollard JD. Relationship between stress and relapse in multiple sclerosis: part I-important features. Mult Scle. 2006;12(4):453-464.
8. Mitsonis CI, Zervas IA, Mitropoulos PA, et al. The impact of stressful life events on risk of relapse in women with multiple sclerosis. prospective study [published online ahead of print September 7, 2008]. Eur Psychiatr. 2008;23(7):497-504.
9. Buljevac D, Hop WCJ, Reedeker W, et al. Self-reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ. 2003;327(7416):646.
10. Wingerchuk DM. Supplementing our understanding of vitami. and multiple sclerosis [published online ahead of print May 5, 2010]. Neurolog. 2010;74(23):1846-1847.
11. Heese O, Schmidt M, Nickel S, et al; German Glioma Network. Complementary therapy use in patients with glioma: an observational study. Neurolog. 2010;75(24):2229-2235.
12. Bowling AC, Stewart TM. Current complementary and alternative therapies for multiple sclerosis. Curr Treat Options Neuro. 2003;5(1):55-68.
13. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs and patterns of use. Eng. Me. 1993;328(4):246-252.
14. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results o. follow-up national survey. JAMA. 1998;280(18):1569-1575.
15. Avonex [package insert]. Cambridge, MA: Biogen Idec Inc; 2006.
16. Rebif [package insert]. New York, NY: Pfizer Inc; 2008.
17. Betaseron [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals; 2007.
18. Copaxone [package insert]. Kansas City, MO: Teva Neuroscience Inc; 2007.
19. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis [published online ahead of print January 20, 2010). Eng. Me. 2010;362(5):402-415.
20. Sobieraj DM. Fingolimod. potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis. Formulary. 2010;45:245-251.
21. Rosenzweig TM, Hartman S, MacKenzie E. Disease-modifying therapy in adult relapsing-remitting multiple sclerosis. Formular. 2010;45:252-262.
22. Sadovnik AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurolog. 1996;46(3):628-632.
23. Feinstein A. Multiple sclerosis, depression and suicide [editorial]. BMJ. 1997; 315(7110):691-692.
24. Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. Neurol Neurosurg Psychiatr. 1992;55(7):542-545.
25. Furnham A, Kirkcaldy B. The health beliefs and behaviors of orthodox and complementary medicine clients. B. Clin Psycho. 1996;35(pt 1):49-61.
26. Schwartz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis [published online ahead of print July 16, 2008]. Mult Scle. 2008;14(8):1113-1119.
27. Defining and describing complementary and alternative medicine. Panel on Definition and Description, CAM Research Methodology Conference, April 1995. Altern Ther Health Me. 1997;3(2):49-57.
28. Nayak S, Matheis RJ, Schoenberger NE, Shiflett SC. Use of unconventional therapies by individuals with multiple sclerosis. Clin Rehabi. 2003;17(2):181-191.
29. Hague T, Andrews PL, Barber J, Naughton DP. Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases. Behav Pharmaco. 2006;17(5-6):425-430.
30. Vincent C, Furnham A. Why do patients turn to complementary medicine? an empirical study. B. Clin Psycho. 1996;35(pt 1):37-48.
31. Bashir K. Current immunotherapy for demyelinating diseases [editorial]. Arch Neurol. 2002;59(5):726-731.
32. Astin JA. Why patients use alternative medicine. JAMA. 1998;279(19):1548-1553.
33. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results o. follow-up national survey. JAMA. 1998;280(18):1569-1575.
34. Stenager E, Stenager EN, Knudsen L, Jensen K. The use of non-medical/alternative treatment in multiple sclerosis. 5 year follow-up study. Acta Neurol Bel. 1995;95(1):18-22.
35. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitami. levels in people with multiple sclerosis and community controls in Tasmania, Australia [published online ahead of print April 11, 2007]. Neuro. 2007;254(5):581-590.
36. Kragt J, van Amerongen B, Killestein J, et al. Higher levels of 25-hydroxyvitami. are associated wit. lower incidence of multiple sclerosis only in women [published online ahead of print August 13, 2008]. Mult Scle. 2009;15(1):9-15.
37. Brown SJ. The role of vitami. in multiple sclerosis. Ann Pharmacothe. 2006;40(6):1158-1161.
38. Liuzzi GM, Latronico T, Rossano R, Viggiani S, Fasano A, Riccio P. Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells: implications for complementary multiple sclerosis treatment. Neurochem Re. 2007;32(12):2184-2193.
39. Aupperle RL, Denney DR, Lynch SG, Carlson SE, Sullivan DK. Omega-3 fatty acids and multiple sclerosis: relationship to depression. Behav Me. 2008;31(2):127-135.
40. Simpso. Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitami. is associated with lower relapse risk in multiple sclerosis. Ann Neuro. 2010;68(2):193-203.
41. Farinotti M, Simi S, Di Pietrantonj C, et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Re. 2007;(1):CD004192.
42. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scan. 2000;102(3):143-149.
43. Goodin DS; Northern California MS Study Group. Survey of multiple sclerosis in northern California. Mult Scle. 1999;5(2):78-88.
44. Stuifbergen AK, Blozis SA, Harrison TC, Becker HA. Exercise, functional limitations, and quality of life. longitudinal study of persons with multiple sclerosis. Arch Phys Med Rehabi. 2006;87(7):935-943.
45. Prakash RS, Snook EM, Erickson KI. Cardiorespiratory fitness. predictor of cortical plasticity in multiple sclerosis. Neuroimag. 2007;34(3):1238-1244.
46. Launsø L, Haahr N. Bridge building and integrative treatment of people with multiple sclerosis: research-based evaluation o. team-building process. Complement Integr Me. 2007;4:1(article 7).
47. Romberg A, Virtanen A, Ruutiainen J, et al. Effects o. 6-month exercise program on patients with multiple sclerosis. randomized study. Neurology. 2004;63(11):2034-2048.
48. Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. Neuro. 2005;252(7):839-845.
49. Kileff J, Ashburn A. pilot study of the effect of aerobic exercise on people with moderate disability multiple sclerosis. Clin Rehabil. 2005;19(2):165-169.
50. Mann JM, Steele KM. The effect of osteopathic manipulative treatment on gait disturbance in multiple sclerosis patients. Am Acad Osteopath. 2004;14(3):27-31.
51. Yates HA, Vardy TC, Kuchera ML, Ripley BD, Johnson JC. Effects of osteopathic manipulative treatment and concentric and eccentric maximal-effort exercise on women with multiple sclerosis. pilot study. Am Osteopath Asso. 2002;102(5):267-275.
52. Gillis AC, Swanson RL II, Janora D, Venkataraman V. Use of osteopathic manipulative treatment to manage compensated trendelenburg gait caused by sacroiliac somatic dysfunction. Am Osteopath Asso. 2010;110(2):81-86.
53. Surakka J, Romberg A, Ruutiainen J, et al. Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis. randomized controlled trial. Clin Rehabi. 2004;18(7):737-746.